| scholarly article | Q13442814 |
| P50 | author | Dennis R. Burton | Q56331320 |
| Hui-Wen Chang | Q56447041 | ||
| Michael S Seaman | Q56474031 | ||
| Thiago Yukio Kikuchi Oliveira | Q56490386 | ||
| Dan H. Barouch | Q60489346 | ||
| Mark G. Lewis | Q66732036 | ||
| Joseph P. Nkolola | Q68690722 | ||
| Pascal Poignard | Q72530329 | ||
| Kathryn E Stephenson | Q80341692 | ||
| Florian Klein | Q89519296 | ||
| Karthik Shekhar | Q112971454 | ||
| Erica N Borducchi | Q114291820 | ||
| Brian Moldt | Q114313962 | ||
| Michel C. Nussenzweig | Q24804686 | ||
| P2093 | author name string | Kaitlin M Smith | |
| Arup K Chakraborty | |||
| James R Perry | |||
| James B Whitney | |||
| Srisowmya Sanisetty | |||
| Jinyan Liu | |||
| Stephen Blackmore | |||
| Sanjana Gupta | |||
| Matthew Beck | |||
| Crystal Cabral | |||
| Jeffrey Y Smith | |||
| William Rinaldi | |||
| P2860 | cites work | Increasing the potency and breadth of an HIV antibody by using structure-based rational design | Q24631510 |
| HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. | Q37259407 | ||
| Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys | Q37355237 | ||
| T-cell vaccination reduces simian immunodeficiency virus levels in semen | Q37365363 | ||
| A novel, rapid method to detect infectious HIV-1 from plasma of persons infected with HIV-1. | Q39745962 | ||
| Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays | Q39988991 | ||
| Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys | Q43183487 | ||
| Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys | Q43212235 | ||
| Development and homeostasis of T cell memory in rhesus macaque | Q45882091 | ||
| Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies | Q57226425 | ||
| Antibodies in HIV-1 vaccine development and therapy | Q27011574 | ||
| Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 | Q27644478 | ||
| Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 | Q27663293 | ||
| Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding | Q27670829 | ||
| Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies | Q27674878 | ||
| Broad and potent neutralization of HIV-1 by a gp41-specific human antibody | Q27675131 | ||
| Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans | Q27678062 | ||
| Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120 | Q27678306 | ||
| Restricting HIV-1 pathways for escape using rationally designed anti–HIV-1 antibodies | Q27678352 | ||
| Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target | Q29547347 | ||
| Broad neutralization coverage of HIV by multiple highly potent antibodies | Q29615361 | ||
| Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody | Q29618366 | ||
| Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 | Q29619511 | ||
| Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues | Q30644992 | ||
| Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques | Q33826773 | ||
| Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. | Q33860721 | ||
| Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. | Q34185625 | ||
| Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals | Q34962766 | ||
| Durable mucosal simian immunodeficiency virus-specific effector memory T lymphocyte responses elicited by recombinant adenovirus vectors in rhesus monkeys | Q35363320 | ||
| Evidence for persistent, occult infection in neonatal macaques following perinatal transmission of simian-human immunodeficiency virus SF162P3 | Q35635083 | ||
| Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys | Q35729899 | ||
| Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies | Q35857254 | ||
| Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection | Q36099376 | ||
| Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies | Q36171962 | ||
| Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys | Q36246220 | ||
| Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses | Q36693991 | ||
| Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248 | Q37109548 | ||
| HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice | Q37236504 | ||
| Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques | Q37252831 | ||
| P433 | issue | 7475 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| monoclonal antibody | Q422248 | ||
| P304 | page(s) | 224-228 | |
| P577 | publication date | 2013-10-30 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys | |
| P478 | volume | 503 |
| Q36548103 | A Case of Long-Term Seronegative Human Immunodeficiency Virus (HIV) Infection: The Importance of the Humoral Response to HIV |
| Q40628557 | A Micro-Polyethylene Glycol Precipitation Assay as a Relative Solubility Screening Tool for Monoclonal Antibody Design and Formulation Development. |
| Q30379545 | A Multiple siRNA-Based Anti-HIV/SHIV Microbicide Shows Protection in Both In Vitro and In Vivo Models |
| Q35827024 | A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo |
| Q100755368 | A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch |
| Q38542411 | A constant threat for HIV: Fc-engineering to enhance broadly neutralizing antibody activity for immunotherapy of the acquired immunodeficiency syndrome |
| Q38165451 | A cure for AIDS: a matter of timing? |
| Q40844843 | A dendritic cell targeted vaccine induces long-term HIV-specific immunity within the gastrointestinal tract |
| Q35298899 | A mammalian cell based FACS-panning platform for the selection of HIV-1 envelopes for vaccine development |
| Q36028475 | A new hypothesis on HIV cure |
| Q49772736 | A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys. |
| Q41930708 | A single gp120 residue can affect HIV-1 tropism in macaques. |
| Q37450695 | A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges |
| Q52584556 | A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection. |
| Q92111662 | AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region |
| Q92153012 | AAV-delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challenges |
| Q90663185 | Accurate Prediction for Antibody Resistance of Clinical HIV-1 Isolates |
| Q36702114 | Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens |
| Q36250921 | Activation and lysis of human CD4 cells latently infected with HIV-1 |
| Q41249890 | Adenovirus-Vectored Broadly Neutralizing Antibodies Directed Against gp120 Prevent Human Immunodeficiency Virus Type 1 Acquisition in Humanized Mice |
| Q36737063 | Advances and hope for perinatal HIV remission and cure in children and adolescents |
| Q85549182 | Almighty antibodies? A new wave of antibody-based approaches aims to combat HIV |
| Q28545185 | An efficiently cleaved HIV-1 clade C Env selectively binds to neutralizing antibodies |
| Q35920037 | Animal models in HIV-1 protection and therapy |
| Q91296268 | Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies |
| Q39108744 | Anti-retroviral antibody FcγR-mediated effector functions |
| Q58572618 | Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies |
| Q28082033 | Antibodies for HIV prevention in young women |
| Q59052828 | Antibodies pose a double threat to HIV |
| Q33786443 | Antibody 10-1074 suppresses viremia in HIV-1-infected individuals |
| Q27683540 | Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike |
| Q57039969 | Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys |
| Q35575206 | Antibody engineering for increased potency, breadth and half-life |
| Q26991572 | Antibody responses to envelope glycoproteins in HIV-1 infection |
| Q90677040 | Antibody responses to the HIV-1 envelope high mannose patch |
| Q36977744 | Antibody therapy for Ebola: is the tide turning around? |
| Q33946158 | Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization |
| Q38812544 | Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells |
| Q40196246 | Antibody-mediated immunotherapy against chronic hepatitis B virus infection |
| Q59339950 | Antibody-mediated prevention and treatment of HIV-1 infection |
| Q37586965 | Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus |
| Q35069151 | Antigenic requirement for Gag in a vaccine that protects against high-dose mucosal challenge with simian immunodeficiency virus. |
| Q38598484 | Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents? |
| Q37719187 | Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope |
| Q41807715 | Association between HIV-1 coreceptor usage and resistance to broadly neutralizing antibodies |
| Q30352300 | Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies. |
| Q36238031 | B cells and antibodies in the defense against Mycobacterium tuberculosis infection |
| Q33412776 | Back to the future: recombinant polyclonal antibody therapeutics |
| Q40373085 | Beyond Viral Neutralization |
| Q47602559 | Beyond binding: antibody effector functions in infectious diseases. |
| Q37073319 | Biphasic CD8+ T-Cell Defense in Simian Immunodeficiency Virus Control by Acute-Phase Passive Neutralizing Antibody Immunization. |
| Q37145901 | Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency |
| Q36334359 | Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization. |
| Q38992408 | Bispecific antibodies for viral immunotherapy |
| Q57808733 | Bispecific antibodies: potential immunotherapies for HIV treatment |
| Q35973601 | Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells |
| Q59350084 | Blocking HIV-1 replication: are Fc-Fcγ receptor interactions required? |
| Q92280921 | Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope |
| Q35831895 | Broadening of Virus-Specific CD8+ T-Cell Responses Is Indicative of Residual Viral Replication in Aviremic SIV Controllers |
| Q33592852 | Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System |
| Q28073939 | Broadly Neutralizing Antibodies for HIV Eradication |
| Q40679052 | Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design |
| Q39001126 | Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers |
| Q34204325 | Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity |
| Q92768003 | Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic |
| Q35032263 | Broadly neutralizing antibodies abrogate established hepatitis C virus infection |
| Q34180174 | Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice |
| Q92962446 | Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities |
| Q57815702 | Broadly neutralizing antibodies in HIV-1 treatment and prevention |
| Q34583552 | Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir |
| Q40410573 | Broadly neutralizing antibodies suppress post-transcytosis HIV-1 infectivity. |
| Q40055103 | Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge |
| Q34262089 | Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes |
| Q35595846 | Broadly neutralizing antibody and the HIV reservoir in acute HIV infection: a strategy toward HIV remission? |
| Q98906656 | Broadly neutralizing plasma antibodies effective against autologous circulating viruses in infants with multivariant HIV-1 infection |
| Q38437455 | CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies. |
| Q37323948 | CD4-mimetic sulfopeptide conjugates display sub-nanomolar anti-HIV-1 activity and protect macaques against a SHIV162P3 vaginal challenge |
| Q38527822 | Can HIV-1-Specific ADCC Assist the Clearance of Reactivated Latently Infected Cells? |
| Q35686912 | Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent |
| Q38794293 | Cell and gene therapy strategies to eradicate HIV reservoirs |
| Q38862056 | Challenges and strategies for the eradication of the HIV reservoir |
| Q36258203 | Chemokine-adjuvanted electroporated DNA vaccine induces substantial protection from simian immunodeficiency virus vaginal challenge |
| Q58792007 | Circulating and intrahepatic antiviral B cells are defective in hepatitis B |
| Q54979433 | Cleavage-Independent HIV-1 Trimers From CHO Cell Lines Elicit Robust Autologous Tier 2 Neutralizing Antibodies. |
| Q37002517 | Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies. |
| Q36079024 | Competitive exclusion by autologous antibodies can prevent broad HIV-1 antibodies from arising |
| Q41610618 | Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains |
| Q38673539 | Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir. |
| Q40173474 | Comprehensive Mapping of HIV-1 Escape from a Broadly Neutralizing Antibody |
| Q35217426 | Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer |
| Q27468870 | Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play |
| Q36319309 | Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library |
| Q74440310 | Crowd-funded HIV vaccine project sparks debate |
| Q30397595 | Current views on the potential for development of a HIV vaccine |
| Q38539190 | Defeating AIDS--advancing global health |
| Q91983265 | Delayed vaginal SHIV infection in VRC01 and anti-α4β7 treated rhesus macaques |
| Q37593171 | Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160. |
| Q41611835 | Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. |
| Q92373152 | Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41 |
| Q38558730 | Development of an AIDS vaccine using Sendai virus vectors |
| Q38989507 | Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits |
| Q39238361 | Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies |
| Q38962226 | Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope |
| Q35691113 | Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization |
| Q57003103 | Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies |
| Q36105672 | Dose-response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies |
| Q34594036 | Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies. |
| Q36266486 | Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells |
| Q37213491 | Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch |
| Q35974409 | Early Antiretroviral Therapy in South African Children Reduces HIV-1-Infected Cells and Cell-Associated HIV-1 RNA in Blood Mononuclear Cells. |
| Q33762877 | Early antibody therapy can induce long-lasting immunity to SHIV |
| Q41102458 | Early antiretroviral therapy in children perinatally infected with HIV: a unique opportunity to implement immunotherapeutic approaches to prolong viral remission |
| Q34594726 | Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection |
| Q37171570 | Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques |
| Q37624842 | Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption |
| Q34687653 | Emerging concepts on T follicular helper cell dynamics in HIV infection |
| Q34531219 | Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity |
| Q30490945 | Engineering antibody-like inhibitors to prevent and treat HIV-1 infection |
| Q38717198 | Engineering broadly neutralizing antibodies for HIV prevention and therapy |
| Q93020607 | Engineering of a Lectibody Targeting High-Mannose-Type Glycans of the HIV Envelope |
| Q34533041 | Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants |
| Q37286064 | Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors |
| Q34593860 | Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo |
| Q40471543 | Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1). |
| Q37021717 | Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques |
| Q34594513 | Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits. |
| Q38977425 | Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection |
| Q38992740 | Evolution of B cell analysis and Env trimer redesign |
| Q35862420 | Exceptional Antibodies Produced by Successive Immunizations |
| Q41930052 | Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV. |
| Q34869927 | Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication |
| Q47547492 | FUNCTIONAL OPTIMIZATION OF BROADLY NEUTRALIZING HIV-1 ANTIBODY 10E8 BY PROMOTING MEMBRANE INTERACTIONS. |
| Q37184296 | Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies |
| Q59350085 | Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques |
| Q47945550 | Fcγ Receptor Function and the Design of Vaccination Strategies |
| Q38615357 | Fcγ receptor pathways during active and passive immunization |
| Q47193141 | Fitness landscape of the human immunodeficiency virus envelope protein that is targeted by antibodies. |
| Q47633699 | From empiricism to rational design: a personal perspective of the evolution of vaccine development |
| Q35168642 | Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody. |
| Q58586699 | Functional cure of HIV: the scale of the challenge |
| Q64093088 | Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals |
| Q38992744 | Genetic and structural analyses of affinity maturation in the humoral response to HIV-1. |
| Q34205040 | Genetic substructure in cynomolgus macaques (Macaca fascicularis) on the island of Mauritius |
| Q38764547 | Germline-targeting immunogens |
| Q42148324 | Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance |
| Q90701830 | Griffithsin Retains Anti-HIV-1 Potency with Changes in gp120 Glycosylation and Complements Broadly Neutralizing Antibodies PGT121 and PGT126 |
| Q42693778 | HIV Prevention and Treatment Fields Join Forces |
| Q37293480 | HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies |
| Q36249933 | HIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions |
| Q39108716 | HIV antibodies for treatment of HIV infection |
| Q27026662 | HIV broadly neutralizing antibody targets |
| Q37098202 | HIV cure research: a formidable challenge |
| Q34410446 | HIV cure research: advances and prospects |
| Q41216521 | HIV reservoirs as obstacles and opportunities for an HIV cure |
| Q41358254 | HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations |
| Q27002180 | HIV therapeutic vaccines: moving towards a functional cure |
| Q38682077 | HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV. |
| Q34531858 | HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption |
| Q35172770 | HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development |
| Q26865803 | HIV-1 functional cure: will the dream come true? |
| Q28086826 | HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth |
| Q34657046 | HIV-1 neutralizing antibody response and viral genetic diversity characterized with next generation sequencing |
| Q26740042 | HIV-1 prophylactic vaccines: state of the art |
| Q27324184 | HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization |
| Q40940285 | HIV-1 resistance to neutralizing antibodies: Determination of antibody concentrations leading to escape mutant evolution |
| Q47254280 | HIV-1 superinfection can occur in the presence of broadly neutralizing antibodies |
| Q34527469 | HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. |
| Q47399269 | HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells |
| Q45857664 | HIV: Antibodies advance the search for a cure |
| Q41690058 | HIV: Potency needs constancy |
| Q42244082 | HIV: advancing the antibody approach |
| Q40061438 | Hidden Lineage Complexity of Glycan-Dependent HIV-1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer |
| Q52571192 | Highlights from the 8th International Workshop on HIV Persistence during Therapy, 12-15 December 2017, Miami, FL, USA. |
| Q42318283 | Highlights from the Third Biennial Strategies for an HIV Cure Meeting: 14-16 November 2016, Bethesda, MD, USA. |
| Q36481483 | Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs |
| Q36757139 | Human Rhinovirus Presenting 4E10 Epitope of HIV-1 MPER Elicits Neutralizing Antibodies in Human ICAM-1 Transgenic Mice |
| Q39459609 | Humanized Mouse Models for Human Immunodeficiency Virus Infection. |
| Q33620546 | Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection |
| Q35600028 | Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function |
| Q30362489 | Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure? |
| Q38219407 | Immunologic Basis for Long HCDR3s in Broadly Neutralizing Antibodies Against HIV-1. |
| Q33896523 | Immunologic strategies for HIV-1 remission and eradication |
| Q45324321 | Immunological and virological characteristics of human immunodeficiency virus type 1 superinfection: implications in vaccine design |
| Q38924824 | Immunotherapeutic strategies for sexually transmitted viral infections: HIV, HSV and HPV. |
| Q38601426 | Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus? |
| Q58724429 | Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies |
| Q36601983 | Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID "Meet the Experts" 2015 Workshop Summary |
| Q35076711 | Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes |
| Q35760429 | In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice |
| Q90616717 | In Vivo Validation of the Viral Barcoding of Simian Immunodeficiency Virus SIVmac239 and the Development of New Barcoded SIV and Subtype B and C Simian-Human Immunodeficiency Viruses |
| Q40285134 | In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses |
| Q35743897 | Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies |
| Q39113783 | Increased frequencies of CD8+CD57+ T cells are associated with antibody neutralization breadth against HIV in viraemic controllers |
| Q47110966 | Increasing the Clinical Potential and Applications of Anti-HIV Antibodies |
| Q89824091 | Induction of Transient Virus Replication Facilitates Antigen-Independent Isolation of SIV-Specific Monoclonal Antibodies |
| Q60301098 | Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier |
| Q37661770 | International AIDS Society global scientific strategy: towards an HIV cure 2016. |
| Q64283447 | Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques |
| Q38998925 | Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies |
| Q36309003 | Longitudinal dynamics of the HIV-specific B cell response during intermittent treatment of primary HIV infection |
| Q36239578 | Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting |
| Q36531018 | Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies |
| Q28071420 | Might dolutegravir be part of a functional cure for HIV? |
| Q36112751 | Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. |
| Q27322403 | Molecular evolution of broadly neutralizing Llama antibodies to the CD4-binding site of HIV-1 |
| Q92883468 | Monoclonal Antibody 2C6 Targets a Cross-Clade Conformational Epitope in gp41 with Highly Active Antibody-Dependent Cell Cytotoxicity |
| Q27312050 | Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers |
| Q37415418 | Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding |
| Q36161508 | NK Cells Expressing the Inhibitory Killer Immunoglobulin-Like Receptors (iKIR) KIR2DL1, KIR2DL3 and KIR3DL1 Are Less Likely to Be CD16+ than Their iKIR Negative Counterparts |
| Q59359574 | Nanotechnology approaches to eradicating HIV reservoirs |
| Q40052007 | Natural Killer (NK) Cell Education Differentially Influences HIV Antibody-Dependent NK Cell Activation and Antibody-Dependent Cellular Cytotoxicity |
| Q37510242 | Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection |
| Q35677620 | Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas |
| Q39206567 | Neutralization resistant HIV-1 primary isolates from antiretroviral naïve chronically infected children in India |
| Q40120996 | Neutralizing Antibodies Against a Specific Human Immunodeficiency Virus gp41 Epitope are Associated With Long-term Non-progressor Status |
| Q59358562 | Neutralizing Antibody-Based Prevention of Cell-Associated HIV-1 Infection |
| Q34550046 | Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success |
| Q47566038 | Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against clade B clinical isolates produced in peripheral blood mononuclear cells |
| Q90390305 | Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound |
| Q37025857 | Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques. |
| Q38238424 | New pharmacological strategies to fight enveloped viruses |
| Q47139556 | Non-Neutralizing Antibodies Directed against HIV and Their Functions |
| Q38915896 | Novel immunological strategies for HIV-1 eradication |
| Q38643834 | Of Mice, Macaques, and Men: Broadly Neutralizing Antibody Immunotherapy for HIV-1. |
| Q50800667 | On plasma cell longevity or brevity. |
| Q35974269 | Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection |
| Q36263769 | Optimal Sequential Immunization Can Focus Antibody Responses against Diversity Loss and Distraction |
| Q92519133 | Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs |
| Q47269868 | Optimization of the EC26-2A4 epitope in the gp41 membrane proximal external region (MPER) targeted by neutralizing antibodies from an elite controller |
| Q27644646 | Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design |
| Q38773102 | Paediatric HIV infection: the potential for cure |
| Q47548101 | Passive immunotherapy of viral infections: 'super-antibodies' enter the fray |
| Q34230556 | Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques |
| Q39305961 | Pathogenic infection of Rhesus macaques by an evolving SIV-HIV derived from CCR5-using envelope genes of acute HIV-1 infections |
| Q28068018 | Patterns of HIV/SIV Prevention and Control by Passive Antibody Immunization |
| Q91719970 | Peptide-Based Vaccines: Current Progress and Future Challenges |
| Q38808266 | Persistent HIV-1 replication during antiretroviral therapy |
| Q35216862 | Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques |
| Q40088787 | Potent In Vivo NK Cell-mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-bispecific and Hexavalent Broadly Neutralizing Fusion Protein. |
| Q38180645 | Practical considerations in gene therapy for HIV cure |
| Q36286484 | Pre-existing neutralizing antibody mitigates B cell dysregulation and enhances the Env-specific antibody response in SHIV-infected rhesus macaques |
| Q33638320 | Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters. |
| Q93105589 | Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir |
| Q47136810 | Prediction of HIV-1 sensitivity to broadly neutralizing antibodies shows a trend towards resistance over time. |
| Q64096904 | Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features |
| Q57093617 | Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1 |
| Q42215329 | Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. |
| Q94547060 | Promise and Progress of an HIV-1 Cure by Adeno-Associated Virus Vector Delivery of Anti-HIV-1 Biologics |
| Q37621530 | Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies |
| Q35569901 | Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life |
| Q35974961 | Protection against SHIV Challenge by Subcutaneous Administration of the Plant-Derived PGT121 Broadly Neutralizing Antibody in Macaques |
| Q41933482 | Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. |
| Q58585537 | Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART |
| Q35973587 | Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys |
| Q92376528 | Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection |
| Q50351069 | Rapid Sequencing of Complete env Genes from Primary HIV-1 Samples. |
| Q34174815 | Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36. |
| Q28068946 | Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies |
| Q26766628 | Recent update in HIV vaccine development |
| Q38718435 | Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs |
| Q59355458 | Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117 |
| Q89467843 | Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody |
| Q28075274 | Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design |
| Q48507985 | Review of Current Cell-Penetrating Antibody Developments for HIV-1 Therapy. |
| Q56995988 | Robotic selection for the rapid development of stable CHO cell lines for HIV vaccine production |
| Q50011228 | Role of framework mutations and antibody flexibility in the evolution of broadly neutralizing antibodies. |
| Q89996173 | Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial |
| Q40076041 | Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers |
| Q35641498 | Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env. |
| Q35980789 | Specific Elimination of Latently HIV-1 Infected Cells Using HIV-1 Protease-Sensitive Toxin Nanocapsules |
| Q52338929 | Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope. |
| Q27683553 | Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers |
| Q34782382 | Structural evolution of glycan recognition by a family of potent HIV antibodies |
| Q26829461 | Structural insights on the role of antibodies in HIV-1 vaccine and therapy |
| Q30358358 | Structural plasticity of the Semliki Forest virus glycome upon interspecies transmission. |
| Q35102339 | Suppression of Fcγ-receptor-mediated antibody effector function during persistent viral infection |
| Q58583636 | Synthetic HIV V3 Glycopeptide Immunogen Carrying a N334 N-Glycan Induces Glycan-Dependent Antibodies with Promiscuous Site Recognition |
| Q34361120 | Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge |
| Q48270835 | Systematic Synthesis and Binding Study of HIV V3 Glycopeptides Reveal the Fine Epitopes of Several Broadly Neutralizing Antibodies. |
| Q37338339 | Systemic administration of an HIV-1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization |
| Q37246321 | Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies |
| Q52570452 | Tandem bispecific broadly neutralizing antibody - a novel approach to HIV-1 treatment. |
| Q35985519 | Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability |
| Q35833324 | Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells |
| Q59357558 | Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry |
| Q54210140 | Targeting the Latent Reservoir for HIV-1. |
| Q64060305 | The Antibodiome-Mapping the Humoral Immune Response to HIV |
| Q35686970 | The Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single Infection |
| Q38505356 | The EPIICAL project: an emerging global collaboration to investigate immunotherapeutic strategies in HIV-infected children |
| Q99637166 | The influence of proline isomerization on potency and stability of anti-HIV antibody 10E8 |
| Q52430553 | The latest evidence for possible HIV-1 curative strategies. |
| Q38209477 | The maturation of antibody technology for the HIV epidemic |
| Q33997395 | The role of Fc receptors in HIV infection and vaccine efficacy. |
| Q37113972 | The role of Fc receptors in HIV prevention and therapy |
| Q26797466 | The role of Fc-FcγR interactions in IgG-mediated microbial neutralization |
| Q39169410 | Therapeutic HIV vaccines: prior setbacks, current advances, and future prospects |
| Q55084408 | Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys. |
| Q47555891 | Therapeutic efficacy of vectored PGT121 gene delivery in HIV-1-infected humanized mice |
| Q38971085 | Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy |
| Q36972591 | Toward a more accurate view of human B-cell repertoire by next-generation sequencing, unbiased repertoire capture and single-molecule barcoding |
| Q36515149 | Towards HIV-1 remission: potential roles for broadly neutralizing antibodies |
| Q42205072 | Towards a cure for HIV--are we making progress? |
| Q40932044 | Towards a vaccine against HIV: antibodies raised by a gp41 peptide neutralize the virus and inhibit pathogenesis |
| Q40972007 | Trying to cure HIV with immunotherapy: not so simple |
| Q34991017 | Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope |
| Q93078490 | Understudied Factors Influencing Fc-Mediated Immune Responses against Viral Infections |
| Q92479131 | Unusual Cysteine Content in V1 Region of gp120 From an Elite Suppressor That Produces Broadly Neutralizing Antibodies |
| Q38764543 | Use of broadly neutralizing antibodies for HIV-1 prevention |
| Q28077662 | Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research |
| Q36628369 | V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1 |
| Q35071821 | Vaccine-induced plasmablast responses in rhesus macaques: phenotypic characterization and a source for generating antigen-specific monoclonal antibodies |
| Q27007529 | Vaccines for the 21st century |
| Q30390904 | Vaccines, new opportunities for a new society |
| Q35664155 | Vectored antibody gene delivery for the prevention or treatment of HIV infection |
| Q36961578 | Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. |
| Q35823060 | Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification |
| Q40187584 | Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys |
| Q35540033 | Well-ordered trimeric HIV-1 subtype B and C soluble spike mimetics generated by negative selection display native-like properties |
| Q26800992 | What Will It Take to Cure HIV? |
| Q33772637 | Which Antibody Functions are Important for an HIV Vaccine? |
| Q37627236 | Why cure, why now? |
| Q47564080 | eCD4-Ig promotes ADCC activity of sera from HIV-1-infected patients |
Search more.